Ultragenyx Pharmaceutical, Inc. (RARE)
16.48
-0.74
(-4.30%)
USD |
NASDAQ |
Nov 20, 16:00
16.48
0.00 (0.00%)
After-Hours: 20:00
Ultragenyx Pharmaceutical Research and Development Expense (TTM) : 677.22M for Sept. 30, 2026
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| September 30, 2026 | 677.22M |
| June 30, 2026 | 739.82M |
| March 31, 2026 | 736.94M |
| December 31, 2025 | 714.72M |
| September 30, 2025 | 699.19M |
| June 30, 2025 | 652.94M |
| March 31, 2025 | 649.46M |
| December 31, 2024 | 662.32M |
| September 30, 2024 | 644.19M |
| June 30, 2024 | 640.08M |
| March 31, 2024 | 652.39M |
| December 31, 2023 | 643.91M |
| September 30, 2023 | 650.31M |
| June 30, 2023 | 726.36M |
| March 31, 2023 | 712.16M |
| December 31, 2022 | 690.77M |
| September 30, 2022 | 643.30M |
| June 30, 2022 | 520.19M |
| March 31, 2022 | 479.53M |
| December 31, 2021 | 483.91M |
| September 30, 2021 | 482.34M |
| June 30, 2021 | 459.45M |
| March 31, 2021 | 430.07M |
| December 31, 2020 | 398.88M |
| September 30, 2020 | 364.04M |
| Date | Value |
|---|---|
| June 30, 2020 | 376.88M |
| March 31, 2020 | 392.21M |
| December 31, 2019 | 357.36M |
| September 30, 2019 | 345.91M |
| June 30, 2019 | 315.81M |
| March 31, 2019 | 296.60M |
| December 31, 2018 | 294.00M |
| September 30, 2018 | 283.91M |
| June 30, 2018 | 274.28M |
| March 31, 2018 | 255.88M |
| December 31, 2017 | 231.64M |
| September 30, 2017 | 220.86M |
| June 30, 2017 | 209.16M |
| March 31, 2017 | 194.06M |
| December 31, 2016 | 183.20M |
| September 30, 2016 | 177.02M |
| June 30, 2016 | 158.02M |
| March 31, 2016 | 137.79M |
| December 31, 2015 | 114.74M |
| September 30, 2015 | 83.48M |
| June 30, 2015 | 66.63M |
| March 31, 2015 | 54.77M |
| December 31, 2014 | 45.76M |
| September 30, 2014 | 40.65M |
| June 30, 2014 | 34.56M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Ionis Pharmaceuticals, Inc. | 921.08M |
| AbbVie, Inc. | 9.962B |
| Krystal Biotech, Inc. | 53.62M |
| BridgeBio Pharma, Inc. | 536.01M |
| Alnylam Pharmaceuticals, Inc. | 1.559B |